MK-677: The Oral Secretagogue That Mimics Your Body’s Natural Growth Signals - Peptide Match

MK-677: The Oral Secretagogue That Mimics Your Body’s Natural Growth Signals

The discovery of MK-677 changed the conversation by offering a way to trigger the body’s own growth hormone production through a simple oral route. As the first non-peptide compound to successfully mimic the actions of the “hunger hormone” ghrelin, it has become a focal point of research into age-related muscle loss, bone density, and metabolic health.
Man smiling and holding a glass of water in a bright modern kitchen

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What is MK-677?

MK-677, also known by the name ibutamoren, belongs to a class of compounds known as growth hormone secretagogues (GHS). While it is often grouped with peptides like ipamorelin or CJC-1295, it is structurally distinct. MK-677 is a small, non-peptide molecule designed to survive the digestive system, allowing it to be taken in investigational settings as a pill while still reaching the brain and pituitary gland effectively.

One of its most defining characteristics is its long half-life of approximately 24 hours, which allows for a single daily dose to maintain elevated levels of insulin-like growth factor 1 (IGF-1) throughout the day. Despite its popularity in certain wellness circles, it is important to note that MK-677 remains an investigational compound and is not FDA-approved for any medical use. It is also frequently mislabeled as a SARM (selective androgen receptor modulator), though it does not interact with androgen receptors at all.

Fast Facts

FULL NAMEMK-677 (Ibutamoren; also known as L-163,191)
CLASSNon-peptide ghrelin receptor agonist; oral growth hormone secretagogue
PRIMARY ACTIONBinds to GHS-R1a receptors to trigger pulsatile growth hormone release and sustained IGF-1 elevation
ADMINISTRATIONInvestigational, swallowed in research settings
HALF-LIFEAbout 24 hours
RESEARCHAge-related muscle loss, bone density, nitrogen balance, and metabolic rate
REGULATORY STATUSInvestigational; not FDA approved for any indication

How Does MK-677 Work?

The mechanism behind MK-677 is centered on its ability to mimic ghrelin, a hormone produced in the stomach that is best known for its role in signaling hunger. However, ghrelin also serves as a critical regulator of the growth hormone axis by traveling to the brain and binding to specific receptors.

MK-677 works by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and the hypothalamus. By mimicking ghrelin at this receptor, it signals the pituitary to release growth hormone in a series of natural-feeling pulses. This is a key distinction from direct growth hormone injections, which provide a flat, constant level of the hormone that can sometimes suppress the body’s own production over time.1

Once the growth hormone is released, it travels to the liver and triggers the production of insulin-like growth factor 1 (IGF-1). Because MK-677 has a long half-life, it provides a sustained signal that keeps IGF-1 levels elevated for a full 24 hours. This sustained elevation is associated with many of the primary effects seen in research, such as changes in muscle mass and bone remodeling.1,2

Unlike some synthetic growth signals, MK-677 does not override the body’s natural “brakes.” The hormone somatostatin, which acts to stop growth hormone release when levels are high enough, remains active. This ensures that the growth hormone is released in a pulsatile manner that respects the body’s internal feedback loops, reducing the risk of the extreme hormonal imbalances seen with some older compounds.1

The structural design of MK-677 allows it to bypass the need for injections entirely. Most growth hormone secretagogues are peptides, which are broken down by stomach acid before they can reach the bloodstream. MK-677 was specifically engineered as a non-peptide molecule that remains stable in the digestive tract, making it the only compound in its class that can be effectively swallowed.1

What Does the Research Say?

The research on MK-677 is particularly robust because it has been evaluated in several long-term, randomized controlled trials involving human participants. These studies have primarily focused on how the compound affects body composition, bone health, and metabolic function in different populations.

THERAPEUTIC AREAWHAT RESEARCH SUGGESTSEVIDENCE LEVEL
Lean Mass
Average gain of 1.1 kg in healthy older adults over a period of 12 months.1Clinical Trials
Bone DensityIncreased markers of bone remodeling and mineral density in the hip.1Clinical Trials
Metabolic RateSignificant increase in basal metabolic rate within two weeks in obese subjects.2Clinical Trials
Muscle PreservationReversal of nitrogen wasting during periods of low-calorie dieting.3Clinical Trials

Primary Areas of Study

The most cited research on MK-677 is a 12-month clinical trial involving healthy older adults. In this study, participants taking 25 mg of MK-677 daily gained an average of 1.1 kg of lean mass, while the placebo group actually lost muscle mass over the same period. This suggests that the compound was associated with a reversal of age-related muscle loss. However, it is important to note that total body weight also increased, and the compound was not associated with a significant reduction in total body fat in this population.1

Beyond muscle, research has explored how MK-677 influences bone health. In the same 12-month trial, researchers observed a significant increase in markers of bone remodeling. Over time, this was associated with an increase in bone mineral density, particularly in the femoral neck (the hip area). This has led to interest in the compound as a potential tool for addressing the bone thinning that’s common with aging.1,2

In studies involving obese individuals, short-term use of MK-677 was associated with a significant rise in the basal metabolic rate. This increase in calorie burning at rest was noted within just two weeks of starting the compound. Furthermore, research has shown that MK-677 can help the body hold onto protein more effectively during periods of caloric restriction, which is a critical factor in preserving muscle during weight loss or recovery from illness.2,3

Safety Profile

In clinical trials, MK-677 was generally described as having a manageable safety profile, though it is associated with several specific side effects that require careful monitoring. The most common issues reported by participants included a significant increase in appetite, temporary swelling in the legs, and mild muscle aches during the initial weeks of use.1

Important Considerations

Effect on Blood Sugar and InsulinThe most significant metabolic concern found in research is a modest increase in fasting blood glucose levels and a decrease in insulin sensitivity. In long-term trials, fasting glucose rose by an average of 5 mg/dL. For individuals with prediabetes or a family history of metabolic issues, this is a critical area that requires medical oversight.
Not FDA ApprovedMK-677 is strictly an investigational compound. It has not been approved by the FDA for the treatment of any medical condition and cannot be legally marketed as a drug or dietary supplement.
Investigational Use OnlyAny use of MK-677 should be considered purely investigational and should only occur under the direct supervision of a licensed physician who can monitor metabolic markers and overall health.
Appetite and Weight GainBecause it mimics the hunger hormone ghrelin, MK-677 is associated with a significant increase in appetite. This can lead to total weight gain, which may not be desirable, particularly for people focused on fat loss.
Medical Supervision is EssentialBefore considering any compound that influences the growth hormone axis, a thorough evaluation by a healthcare provider is necessary to ensure it is appropriate for your specific health profile and to address potential risks.
The Bottom Line: MK-677 holds a genuinely interesting place among growth hormone secretagogues. It is the only compound in this class with a real body of human clinical trial data, and the only one that can be taken by mouth. In randomized controlled trials, MK-677 was associated with increases in lean mass, elevated IGF-1, and preservation of lean tissue during caloric restriction.1,2,3
At the same time, it is not FDA-approved, its effects on blood sugar are a consistent concern, and the long-term safety picture in humans is not yet fully known. The research covers up to 12 months of use, which is meaningful but not enough to draw conclusions about what happens over many years.
For clinicians and patients exploring growth hormone secretagogues, MK-677 is one of the better-studied options available. But that evidence comes with real caveats, and any use outside of a clinical trial or supervised medical setting carries regulatory and safety risks that should not be taken lightly. As with all investigational compounds, the right place to start is with a qualified healthcare provider who can weigh the individual’s situation against the current data.

Scientific References

  1. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9):601-611.
  2. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, insulin-like growth factor-I, and basal metabolic rate, and modifies body composition. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362-369.
  3. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an oral growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):320-325.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io. 

Ready to take the next step?

Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.

Search Icon